



TTK Healthcare LIMITED

TTKHC:SEC:GJ:214:21

October 29, 2021

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Unaudited Financial Results along with Limited Review Report for the Second
Quarter ended 30th September, 2021**

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Second Quarter ended 30th September, 2021, duly reviewed by the Audit Committee at their meeting held yesterday (i.e.) on 28th October, 2021 and approved by the Board of Directors of the Company at their Meeting held today.

Kindly take the above documents on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(S KALYANARAMAN)
Wholetime Director & Secretary

Encl. : a/a



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2021

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		For the year ended
		(30/09/2021)	(30/06/2021)	(30/09/2020)	(30/09/2021)	(30/09/2020)	(31/03/2021)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from Operations	20,635.55	17,079.12	15,966.63	37,714.67	27,606.30	63,652.79
II.	Other Income	303.77	365.83	215.29	669.60	407.75	1,000.01
III.	Total Income (I + II)	20,939.32	17,444.95	16,181.92	38,384.27	28,014.05	64,652.80
IV.	Expenses						
	(a) Cost of materials consumed	3,564.68	2,591.95	2,669.67	6,156.63	4,276.55	9,891.54
	(b) Purchase of Stock-in-trade	4,496.42	4,280.99	3,588.68	8,777.41	5,769.91	14,876.91
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	262.09	(250.95)	(152.26)	11.14	870.31	405.32
	(d) Employee benefits expense	3,780.20	4,190.85	3,929.87	7,971.05	7,496.98	16,007.53
	(e) Finance Costs	55.43	62.52	58.49	117.95	121.30	222.38
	(f) Depreciation and Amortization Expense	326.09	334.55	343.26	660.64	696.72	1,371.13
	(g) Other Expenses	6,953.77	5,385.82	5,025.97	12,339.59	8,356.33	18,982.59
	Total Expenses (IV)	19,438.68	16,595.73	15,463.68	36,034.41	27,588.10	61,757.40
V.	Profit / (Loss) before Exceptional Items and Tax (III - IV)	1,500.64	849.22	718.24	2,349.86	425.95	2,895.40
VI.	Exceptional Items [Refer Note No.4 below]	249.05	-	809.79	249.05	809.79	809.79
VII.	Profit / (Loss) before Tax (V + VI)	1,749.69	849.22	1,528.03	2,598.91	1,235.74	3,705.19
VIII.	Tax Expense:						
	(1) Current Tax	500.00	280.00	420.00	780.00	420.00	1,225.00
	(2) Deferred Tax	(31.12)	(30.36)	(8.03)	(61.48)	(60.10)	(199.11)
	(3) Tax relating to earlier years [Refer Note No.4 below]	-	-	(1,964.81)	-	(1,964.81)	(1,964.81)
IX.	Profit / (Loss) for the period from Continuing Operations (VII-VIII)	1,280.81	599.58	3,080.87	1,880.39	2,840.65	4,644.11
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expense of Discontinued Operations	-	-	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X -XI)	-	-	-	-	-	-
XIII.	Profit / (Loss) for the period (IX + XII)	1,280.81	599.58	3,080.87	1,880.39	2,840.65	4,644.11
XIV.	Other Comprehensive Income:						
	(A) (i) Items that will not be reclassified subsequently to profit or loss	(78.49)	384.39	130.59	305.90	230.35	315.27
	(ii) Income tax relating to items that will not be reclassified to profit or loss	8.97	(43.13)	(3.25)	(34.16)	2.91	29.88
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]	1,211.29	940.84	3,208.21	2,152.13	3,073.91	4,989.26

Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		For the year ended
		(30/09/2021)	(30/06/2021)	(30/09/2020)	(30/09/2021)	(30/09/2020)	(31/03/2021)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	-	-	27,610.18
XVI.	Earnings per Equity Share (For Continuing Operations):						
	(1) Basic (in Rs.)	9.07	4.24	21.80	13.31	20.10	32.87
	(2) Diluted (in Rs.)	9.07	4.24	21.80	13.31	20.10	32.87
XVII.	Earnings per Equity Share (For Discontinued Operations):						
	(1) Basic (in Rs.)	-	-	-	-	-	-
	(2) Diluted (in Rs.)	-	-	-	-	-	-
XVIII.	Earnings per Equity Share (For Continuing and Discontinued Operations):						
	(1) Basic (in Rs.)	9.07	4.24	21.80	13.31	20.10	32.87
	(2) Diluted (in Rs.)	9.07	4.24	21.80	13.31	20.10	32.87

Notes:

- (1) The above financial results for the Second Quarter and Half-year ended 30th September, 2021 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on 28th October, 2021 and approved by the Board of Directors of the Company at its meeting held on 29th October, 2021 through Video Conferencing (VC).
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) The second wave of CoVID-19 and the extended lockdown during the First Quarter of the Financial year 2021-22 has impacted the business of the Company. However, considering the ongoing vaccination drive and other sustainable actions taken by the Management, both with reference to the environment and its employees' health, the impact has been minimal.

The Company, based on current estimates, expects that the carrying amount of all its assets will be recovered, net of provisions established. However, the impact assessment of CoVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.
- (4) (i) Exceptional Items relating to FY 2021-22: In September, 2021, the Company sold the land admeasuring 4.595 acres held by it at Perungudi Village, Tirunelveli District, Tamil Nadu, on which the Company has earned a profit of Rs.249.05 lakhs.

(ii) Exceptional Items relating to FY 2020-21: The Company's claim in respect of tax benefits due to adjustment of unabsorbed losses and depreciation of the erstwhile TTK Protective Devices Limited and TSL Techno Services Limited which merged with the Company w.e.f. 1st April, 2012, (shown as Contingent Asset in earlier years), has been allowed. The Company has received the revised assessment orders in the previous FY 2020-21 and the refund received is accounted as follows:
 - (a) Rs.809.79 lakhs towards Interest on Tax Refund received is treated as Exceptional Income; and
 - (b) Balance Refund received (net of provisions of Rs.999.74 lakhs considered necessary) of Rs.1,964.81 lakhs has been accounted as Tax Refund relating to earlier years.
- (5) Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- (6) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (7) This Statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

(8) Statement of Assets and Liabilities as at 30th September, 2021:

(Rs. in Lakhs)

Sl. No.	Particulars	As on 30/09/2021	As on 31/03/2021
		Unaudited	Audited
(A)	ASSETS:		
I	Non-Current Assets:		
(a)	Property, Plant and Equipment	7,164.64	7,457.08
(b)	Right of Use Asset	1,082.73	1,062.29
(c)	Capital Work-in-Progress	1.63	44.50
(d)	Other Intangible Assets	12.21	15.35
(e)	Financial Assets	-	-
(i)	Investments	1,622.51	1,316.61
(ii)	Others Financial Assets	231.12	231.88
(f)	Non-current Tax Assets (Net)	822.92	1,081.67
(g)	Deferred Tax Assets (Net)	672.46	645.14
(h)	Other Non-current Assets	113.16	85.50
	Total Non-Current Assets	11,723.38	11,940.02
II	Current Assets:		
(a)	Inventories	7,232.56	7,030.39
(b)	Financial Assets		
(i)	Trade Receivables	7,239.58	5,977.69
(ii)	Cash and Cash Equivalents	1,219.23	955.48
(iii)	Bank balances other than (ii) above	23,572.69	21,813.65
(iv)	Other Financial Assets	723.41	641.59
(c)	Current Tax Assets (Net)	-	-
(d)	Other Current Assets	1,023.30	1,068.34
	Total Current Assets	41,010.77	37,487.14
	TOTAL ASSETS	52,734.15	49,427.16
(B)	EQUITY AND LIABILITIES:		
(1)	Equity		
(a)	Equity Share Capital	1,413.03	1,413.03
(b)	Other Equity	29,355.91	28,051.61
	Equity attributable to owners of the Company	30,768.94	29,464.64
	Total Equity	30,768.94	29,464.64
(2)	Liabilities		
	Non-current Liabilities:		
(a)	Financial Liabilities:		
(i)	Lease Liabilities	137.48	115.77
(b)	Provisions	1,008.47	789.78
(c)	Deferred Revenue Income	207.12	180.71
	Total Non-current Liabilities	1,353.07	1,086.26
	Current Liabilities:		
(a)	Financial Liabilities		
(i)	Borrowings	446.63	1,759.82
(ii)	Lease Liabilities	46.00	38.79
(iii)	Trade Payables:		
(A)	Due to Micro and Small Enterprises	1,560.28	1,940.79
(B)	Due to other than Micro and Small Enterprises	10,813.37	7,819.83
(iv)	Other Financial Liabilities	6,432.31	6,216.73
(b)	Provisions	490.11	490.06
(c)	Current Tax Liabilities (Net)	211.47	140.55
(d)	Other Current Liabilities	611.97	469.69
	Total Current Liabilities	20,612.14	18,876.26
	TOTAL LIABILITIES	21,965.21	19,962.52
	TOTAL EQUITY AND LIABILITIES	52,734.15	49,427.16

(9) Statement of Cash Flow for the Half-year ended 30th September, 2021:

(Rs. in lakhs)

Particulars	For the Half-year ended		For the year ended
	(30/09/2021)	(30/09/2020)	(31/03/2021)
	Unaudited	Unaudited	Audited
Cash Flow from Operating activities:			
Profit before tax	2,598.91	1,235.74	3,705.19
Adjustments for:			
Remeasurements of defined benefit plans	-	-	(126.00)
Depreciation and amortisation Expenses	660.64	696.72	1,371.13
Provision for Doubtful Debts	28.14	-	111.60
Interest paid	117.95	121.30	222.38
Interest received	(645.82)	(1,214.08)	(1,796.49)
(Profit) / Loss on Sale of Assets / Impairment	(249.12)	1.81	10.93
Dividend Income	(5.36)	(3.29)	(7.13)
Operating Profit before Working Capital changes:	2,505.34	838.20	3,491.61
Adjustments for Working Capital changes:			
Inventories	(202.17)	779.31	134.09
Trade Receivables	(1,290.03)	1,683.61	1,587.68
Other Receivables	44.32	84.11	(189.90)
Trade Payables	2,613.03	46.80	1,109.63
Other Liabilities	513.06	1,621.47	1,466.67
Deferred Revenue Income	26.41	-	10.35
Cash generated from Operations:	4,209.96	5,053.50	7,610.13
Less: Direct Taxes paid	618.04	204.83	1,091.14
Add: Direct Taxes received	167.72	3,123.12	3,123.12
Net Cash generated from (used in) Operating Activities	3,759.64	7,971.79	9,642.11
Cash Flow from Investing Activities:			
Purchase of Fixed Assets / Capital advances	(312.56)	(13.26)	(173.27)
Sale of Fixed Assets	254.91	0.42	6.46
Investments in Bank deposits (Net)	(1,759.04)	(6,245.33)	(9,360.71)
Interest received	565.48	1,214.08	1,796.49
Dividend received	5.36	3.29	7.13
Net Cash generated from (used in) Investing Activities	(1,245.85)	(5,040.80)	(7,723.90)
Cash Flow from Financing Activities:			
Borrowings (Net of repayment)	(1,284.27)	(931.16)	(1,069.33)
Interest Paid	(117.95)	(121.30)	(222.38)
Dividend Paid	(847.82)	(423.91)	(423.91)
Net Cash generated from (used in) Financing Activities	(2,250.04)	(1,476.37)	(1,715.62)
Net Increase / (Decrease) in Cash and Cash Equivalents	263.75	1,454.62	202.59
Cash and Cash Equivalents as at the beginning of the year	955.48	752.89	752.89
Total	1,219.23	2,207.51	955.48
Cash and Cash Equivalents as at the end of the year (as per Balance Sheet)	1,219.23	2,207.51	955.48

For TTK HEALTHCARE LIMITED


T T RAGHUNATHAN
Executive Vice ChairmanPlace : Chennai
Date : October 29, 2021

**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2021

(Rs. in lakhs)							
Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		For the year ended
		(30/09/2021)	(30/06/2021)	(30/09/2020)	(30/09/2021)	(30/09/2020)	(31/03/2021)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Segment Revenue: (Sales and Other Operating Income)						
	(a) Pharmaceuticals	8,128.70	6,171.86	6,322.51	14,300.56	10,549.19	23,844.31
	(b) Consumer Products	5,444.84	5,725.69	4,378.85	11,170.53	8,010.44	17,485.02
	(c) Medical Devices	1,405.27	573.34	460.15	1,978.61	730.70	2,673.24
	(d) Protective Devices	3,216.81	2,550.78	2,135.69	5,767.59	3,600.22	9,457.14
	(e) Foods	2,434.33	2,054.92	2,657.87	4,489.25	4,697.88	10,162.14
	(f) Others	5.60	2.53	11.56	8.13	17.87	30.94
	Total	20,635.55	17,079.12	15,966.63	37,714.67	27,606.30	63,652.79
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Net Sales / Income from Operations	20,635.55	17,079.12	15,966.63	37,714.67	27,606.30	63,652.79
2.	Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]						
	(a) Pharmaceuticals	1,722.01	665.77	708.59	2,387.78	855.70	2,707.12
	(b) Consumer Products	318.06	715.36	594.95	1,033.42	1,357.88	2,026.89
	(c) Medical Devices	205.63	(145.94)	(241.25)	59.69	(520.26)	(535.21)
	(d) Protective Devices	(474.04)	3.24	(140.05)	(470.80)	(647.78)	(330.32)
	(e) Foods	(56.66)	(112.68)	69.00	(169.34)	(61.55)	103.47
	(f) Others	4.99	2.89	8.77	7.88	14.20	25.29
	Total	1,719.99	1,128.64	1,000.01	2,848.63	998.19	3,997.24
	Less: Finance Cost	55.43	62.52	58.49	117.95	121.30	222.38
	Less: Unallocable Expenses (Net of Unallocable Income)	(85.13)	216.90	(586.51)	131.77	(358.85)	69.67
	Total Profit (+) / Loss (-) before tax	1,749.69	849.22	1,528.03	2,598.91	1,235.74	3,705.19
		As on 30/09/2021	As on 30/06/2021	As on 30/09/2020	As on 30/09/2021	As on 30/09/2020	As on 31/03/2021
3.	Segment Assets						
	(a) Pharmaceuticals	6,893.59	6,404.63	5,967.16	6,893.59	5,967.16	5,579.36
	(b) Consumer Products	2,634.51	2,691.58	3,255.96	2,634.51	3,255.96	3,025.93
	(c) Medical Devices	4,172.72	3,516.44	3,677.35	4,172.72	3,677.35	3,660.51
	(d) Protective Devices	7,953.90	7,495.76	7,657.09	7,953.90	7,657.09	7,271.38
	(e) Foods	9,515.96	8,917.38	8,699.31	9,515.96	8,699.31	9,082.23
	(f) Others	179.49	175.93	163.99	179.49	163.99	173.72
	Total	31,350.17	29,201.72	29,420.86	31,350.17	29,420.86	28,793.13
	Unallocated	26,485.50	25,644.78	21,138.32	26,485.50	21,138.32	24,766.07
	Total Assets	57,835.67	54,846.50	50,559.18	57,835.67	50,559.18	53,559.20
4.	Segment Liabilities						
	(a) Pharmaceuticals	7,501.43	7,042.58	6,634.10	7,501.43	6,634.10	6,383.04
	(b) Consumer Products	7,436.43	6,105.05	5,292.70	7,436.43	5,292.70	6,589.60
	(c) Medical Devices	1,664.73	1,280.60	1,210.31	1,664.73	1,210.31	1,233.11
	(d) Protective Devices	3,166.93	2,228.80	2,057.07	3,166.93	2,057.07	2,088.98
	(e) Foods	1,631.57	1,341.01	1,741.88	1,631.57	1,741.88	1,582.31
	(f) Others	131.92	132.11	133.97	131.92	133.97	132.94
	Total	21,533.01	18,130.15	17,070.03	21,533.01	17,070.03	18,009.98
	Unallocated	5,533.72	6,310.88	5,939.87	5,533.72	5,939.87	6,084.59
	Total Liabilities	27,066.73	24,441.03	23,009.90	27,066.73	23,009.90	24,094.57

Notes:

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
2. Details of products included in each of the Segments are as below :
 - ❖ Pharmaceuticals include products for both Human and Veterinary use.
 - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc.
 - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
 - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
 - ❖ Foods comprise manufacturing and marketing of Food Products.
 - ❖ "Others" include Printing and Publishing of Maps and Atlases.
3. The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED



T T RAGHUNATHAN
Executive Vice Chairman

Place : Chennai
Date : October 29, 2021

**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30TH SEPTEMBER, 2021

Sl. No.	Particulars	For the Quarter ended			For the Half-year ended		(Rs. in lakhs)
		(30/09/2021)	(30/06/2021)	(30/09/2020)	(30/09/2021)	(30/09/2020)	For the year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Total income from Operations	20,635.55	17,079.12	15,966.63	37,714.67	27,606.30	63,652.79
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	1,500.64	849.22	718.24	2,349.86	425.95	2,895.40
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items) [Refer Note No.6 below]	1,749.69	849.22	1,528.03	2,598.91	1,235.74	3,705.19
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items) [Refer Note No.6 below]	1,280.81	599.58	3,080.87	1,880.39	2,840.65	4,644.11
5.	Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	1,211.29	940.84	3,208.21	2,152.13	3,073.91	4,989.26
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	-	-	27,610.18
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
(a)	Basic (in Rs.)	9.07	4.24	21.80	13.31	20.10	32.87
(b)	Diluted (in Rs.)	9.07	4.24	21.80	13.31	20.10	32.87

Notes:

- (1) The above is an extract of the detailed Statement of Unaudited Financial Results for the Second Quarter and Half-year ended 30th September, 2021, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (2) The full financial results for the Second Quarter and Half-year ended 30th September, 2021 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- (3) These financial results have been reviewed by the Audit Committee at its meeting held on 28th October, 2021 and approved by the Board of Directors of the Company at its meeting held on 29th October, 2021 through Video Conferencing (VC).
- (4) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (5) The second wave of CoVID-19 and the extended lockdown during the First Quarter of the financial year 2021-22 has impacted the business of the Company. However, considering the ongoing vaccination drive and other sustainable actions taken by the Management, both with reference to the environment and its employees' health, the impact has been minimal.
- The Company, based on current estimates, expects that the carrying amount of all its assets will be recovered, net of provisions established. However, the impact assessment of CoVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.
- (6) (i) Exceptional Items relating to FY 2021-22: In September, 2021, the Company sold the land admeasuring 4.595 acres held by it at Perungudi Village, Tirunelveli District, Tamil Nadu, on which the Company has earned a profit of Rs.249.05 lakhs.
- (ii) Exceptional Items relating to FY 2020-21: The Company's claim in respect of tax benefits due to adjustment of unabsorbed losses and depreciation of the erstwhile TTK Protective Devices Limited and TSL Techno Services Limited which merged with the Company w.e.f. 1st April, 2012, (shown as Contingent Asset in earlier years), has been allowed. The Company has received the revised assessment orders in the previous FY 2020-21 and the refund received is accounted as follows:
- (a) Rs.809.79 lakhs towards Interest on Tax Refund received is treated as Exceptional Income; and
- (b) Balance Refund received (net of provisions of Rs.999.74 lakhs considered necessary) of Rs.1,964.81 lakhs has been accounted as Tax Refund relating to earlier years.
- (7) Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 Lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- (8) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
Executive Vice ChairmanPlace : Chennai
Date : October 29, 2021

Independent Auditor's Review Report on review of Interim Financial Results

To the Board of Directors of TTK Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results of **TTK Healthcare Limited** (the "Company"), for the quarter and half year ended 30th September 2021 ("the Statement"), being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Obligations") which has been initialed by us for identification.

Management's Responsibility

2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Auditor's Responsibility

3. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Obligations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm's Registration No. 003990S/S200018


S. Rajeshwari

Partner

Membership No. 024105

Place: Chennai

Date: 29th October 2021

UDIN: 21024105AAAA C12291

